SEC
CLDX icon

Seven Eight Capital’s Celldex Therapeutics CLDX Stock Holding History

Seven Eight Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,000
Closed -$316K – 564
2015
Q3 		$316K Buy
2,000
+1,847
+1,207% +$523K 0.27% 128
2015
Q2 		$58K Buy
+153
New +$60.8K 0.07% 312
2014
Q1 		– Sell
-25
Closed -$9K – 310
2013
Q4 		$9K Buy
+25
New +$9.63K 0.01% 531

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Seven Eight Capital's CLDX Position: Q4 2015 in Review

Seven Eight Capital sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 2,000 shares — an estimated $316K sold.

Seven Eight Capital first reported a position in CLDX in Q4 2013 and held it in 3 quarters. The position peaked at $316K in Q3 2015. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • Seven Eight Capital reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Seven Eight Capital sold 2,000 Celldex Therapeutics shares in Q4 2015, an estimated $316K.
  • Seven Eight Capital first reported a position in Celldex Therapeutics in Q4 2013 and held it in 3 quarters.
  • Seven Eight Capital's Celldex Therapeutics position peaked at $316K in Q3 2015.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on Seven Eight Capital's 13F filing for Q4 2015, filed 16 Feb 2016.